Furthermore, in clinical trials involving a wide range of heart failure patients, regardless of ejection fraction (DAPA-HF trials, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER), SGLT2 inhibitors dapagliflozin and empagliflozin were associated with a significantly decreased risk of cardiovascular death and heart failure hospitalization (12–15). The gene discussed is SLC5A2; the disease is heart failure.